ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Inclusion Criteria: * The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of Stage I-IV (T1-3, N0-2b) of the oropharynx. * The patient's tumor is HPV positive by PCR or ISH assay of tumor biopsy. * The patient is able/eligible to undergo treatment with transoral robotic surgery (TORS) with or without neck dissection and with or without adjuvant radiation therapy or chemoradiation. * The patient is able to understand and give informed consent. * The patient is at least 18 years old. * The patient's ECOG performance status is \</= 2. Exclusion Criteria: * The patient has had prior head and neck squamous cell carcinoma (HNSCC), with the exception of superficial cutaneous basal cell or squamous cell carcinomas. * The patient has active cancer in another part of the body, with the exception of superficial cutaneous basal cell or squamous cell carcinomas * If a cancer survivor, the disease free interval is less than 3 years, with the exception of superficial cutaneous basal cell or squamous cell carcinomas. * If a cancer survivor the patient received prior systemic chemotherapy or radiotherapy * If prior standard-of-care pre-treatment biopsy is inadequate for analysis by immunohistochemistry, and the patient is unwilling to undergo an additional biopsy procedure. * The patient is a prisoner. * The patient has a psychiatric illness or developmental delay which would interfere with understanding of the study and provision of informed consent. * The patient has previously received definitive surgical, radiation, or chemoradiation treatment for HNSCC. * The patient has a history of HIV or other known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions. * Patient is allergic to naproxen or Ibuprofen. * The patient has a history of liver disease. * The patient has a contraindication (e.g. sensitivity/allergy) to both trimethoprim/sulfamethoxazole and ampicillin. * The patient has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)). NOTE: More common devices and prosthetics which include arterial and venous stents, dental and breast implants and venous access devices (e.g. Port-a-Cath or Mediport) are permitted. * Patients who are receiving or may receive future treatment with PI3K or TNFα inhibitors. * Patients who have undergone a major surgery, including surgery for a new artificial implant and/or device, within 6 weeks prior to the initiation of ADXS11-001 treatment. Sponsor must be consulted prior to enrolling subjects on the study who recently had a major surgery or have new artificial implant, and/or devices. * Patients who have a history of listeriosis or prior ADXS11-001 therapy. * Patients with a known allergy to any component of the study treatment formulations. * Pregnancy. The effects of this vaccine on the developing human fetus are unknown. For this reason women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.